Prelude Capital Management, LLC Esperion Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.12 Billion
- Q3 2025
A detailed history of Prelude Capital Management, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 65,327 shares of ESPR stock, worth $189,448. This represents 0.02% of its overall portfolio holdings.
Number of Shares
65,327
Previous 265,588
75.4%
Holding current value
$189,448
Previous $260,000
33.46%
% of portfolio
0.02%
Previous 0.03%
Shares
11 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
113MCall Options Held
643KPut Options Held
769K-
Black Rock Inc. New York, NY14MShares$40.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$35.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.75MShares$28.3 Million0.51% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.06MShares$20.5 Million0.1% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19.4 Million7.68% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $193M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...